September 22, 2023

The applying for the brand new CPT III code was the results of a collaboration between MAPS PBC and COMPASS Pathways to facilitate reimbursement and finally entry to psychedelic therapies within the US, if authorized by the US Meals Drug Administration (FDA). Each firms are working to develop and, topic to FDA approval, commercialize psychedelics as a part of a brand new therapy paradigm for people with psychological well being situations. COMPASS Pathways is conducting a phase 3 program of investigational COMP360 psilocybin remedy in treatment-resistant melancholy (TRD), having already printed positive results within the New England Journal of Medication from its part 2b examine of COMP360 in TRD, within the largest examine of its variety. MAPS PBC has accomplished two phase 3 clinical trials evaluating MDMA-assisted remedy as a possible therapy for post-traumatic stress dysfunction (PTSD), each of which met their pre-specified major and secondary endpoints. This new code could present a mechanism by which these new therapies being developed by COMPASS and MAPS PBC might be reimbursed if they’re authorized by the FDA.

“It is a main step ahead to enabling broad and equitable entry to psychedelic therapies,” stated Kabir Nath, CEO, COMPASS Pathways. “This collaboration with MAPS PBC to develop a brand new CPT code goals to make sure that psychedelic therapies, if authorized, might be built-in into healthcare techniques, reimbursed by payers, and made accessible to the individuals who want them.”

On March 3, 2023 the AMA published the Abstract of Panel Actions which included the acceptance of the brand new CPT III code. The applying was titled, “Steady In-Individual Monitoring and Intervention throughout Psychedelic Treatment Remedy.” CPT III codes are a set of short-term codes assigned to rising applied sciences, providers and procedures. They’re meant for use for information assortment to substantiate extra widespread utilization or to offer documentation for the FDA approval course of.

“Psychedelic-assisted therapies symbolize a possible new frontier within the therapy of psychological well being situations and our high precedence is guaranteeing there’s a path ahead to combine them into the healthcare system, if FDA authorized,” stated Amy Emerson, CEO, MAPS PBC. “Robust collaborations like this one display that by working collectively, we will transfer nearer to our collective purpose of serving to individuals at the moment underserved by present therapies for psychological well being situations.”

About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a psychological well being care firm devoted to accelerating affected person entry to evidence-based innovation in psychological well being. Our focus is on bettering the lives of those that are struggling with psychological well being challenges and who are usually not helped by present therapies. We’re pioneering the event of a brand new mannequin of psilocybin remedy, by which our proprietary formulation of artificial psilocybin, COMP360, is run along side psychological assist. COMP360 has been designated a Breakthrough Remedy by the U.S. Meals and Drug Administration (FDA) and has acquired Modern Licensing and Entry Pathway (ILAP) designation within the UK for treatment-resistant melancholy (TRD). We’ve got commenced a part 3 medical program of COMP 360 psilocybin remedy in TRD, the most important randomised, managed, double-blind psilocybin remedy medical program ever performed. Beforehand, we accomplished a part 2b examine with high line information exhibiting a statistically important (p

Availability of different details about COMPASS Pathways
Traders and others ought to notice that we talk with our traders and the general public utilizing our web site (, our investor relations web site (, and on social media (LinkedIn), together with however not restricted to investor shows and investor truth sheets, US Securities and Trade Fee filings, press releases, public convention calls and webcasts. The data that we submit on these channels and web sites might be deemed to be materials info. Consequently, we encourage traders, the media, and others excited by us to evaluate the data that’s posted on these channels, together with the investor relations web site, regularly. This listing of channels could also be up to date now and again on our investor relations web site and should embody further social media channels. The contents of our web site or these channels, or every other web site that could be accessed from our web site or these channels, shall not be deemed included by reference in any submitting beneath the Securities Act of 1933.

Ahead-looking statements
This press launch comprises forward-looking statements inside the which means of the Non-public Securities Litigation Reform Act of 1995, as amended. In some instances, forward-looking statements could be recognized by terminology similar to “could”, “may”, “will”, “may”, “ought to”, “anticipate”, “intend”, “plan”, “anticipate”, “consider”, “ponder”, “search”, “potential”, “proceed” and “ongoing,” or the destructive of those phrases or different comparable terminology, though not all forward-looking statements comprise these phrases. Ahead-looking statements embody specific or implied statements regarding, amongst different issues, the Firm’s plans and anticipated timing for its part 3 program in TRD and the potential for that or different trials to assist regulatory filings and approvals, the protection or efficacy of its investigational COMP360 psilocybin remedy, together with for therapy of TRD, anorexia nervosa, and PTSD, and COMPASS’s expectations concerning the potential impression of the CPT III codes on reimbursement for and entry to COMP360 psilocybin remedy, if FDA approval is obtained. The forward-looking statements on this press launch are neither guarantees nor ensures, and you shouldn’t place undue reliance on these forward-looking statements as a result of they contain recognized and unknown dangers, uncertainties, and different components, lots of that are past COMPASS’s management and which may trigger precise outcomes, ranges of exercise, efficiency or achievements to vary materially from these expressed or implied by these forward-looking statements.

These dangers, uncertainties, and different components embody, amongst others: medical improvement is prolonged and outcomes are unsure, and subsequently our medical trials could also be delayed or terminated, or could by no means advance; our efforts to acquire advertising approval from the relevant regulatory authorities in any jurisdiction for COMP360 or any of future product candidates could also be unsuccessful; the American Medical Affiliation could change the scope of the CPT III code previous to publication in July 2023, which can negatively impression our expectations concerning reimbursement for COMP360 psilocybin remedy, if authorized, and our efforts to acquire protection and reimbursement for our investigational COMP360 psilocybin remedy, if authorized, could also be unsuccessful; and people dangers and uncertainties described beneath the heading “Threat Elements” in COMPASS’s most up-to-date annual report on Kind 10-Okay or quarterly report on Kind 10-Q and in different studies now we have filed with the U.S. Securities and Trade Fee (“SEC”), which can be found on the SEC’s web site at Besides as required by legislation, COMPASS disclaims any intention or duty for updating or revising any forward-looking statements contained on this press launch within the occasion of latest info, future developments or in any other case. These forward-looking statements are based mostly on COMPASS’s present expectations and communicate solely as of the date hereof.

MAPS Public Profit Company (MAPS PBC) is targeted on creating and commercializing prescription psychedelics to convey higher therapies to these dwelling with psychological well being situations. Based in 2014, MAPS PBC is a subsidiary of the Multidisciplinary Affiliation for Psychedelic Research, a 501(c)(3) non-profit group. For extra info, please go to

COMPASS media: Amy Lawrence, [email protected], +44 7813 777 919
COMPASS traders: Stephen Schultz, [email protected], +1 401 290 7324
MAPS PBC: Blair Clark-Schoeb, [email protected]

Primary Logo